trial

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCTId NCT05106309
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 16 (actual)
Sponsored by Cerevel Therapeutics, LLC
Primary completion 2022-02-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2021-12-29
Primary completion
2022-02-24
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

Cerevel Therapeutics, LLCLead Sponsor

Investigators

1
Matthew Leoni, MD, MBAStudy Director

Sites

1 total
Tempe, United States

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE1
Primary Completion Date
2022-02-24
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
Cerevel Therapeutics, LLC
company
indication
Schizophrenia
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Matthew Leoni, MD, MBA
person